Outcomes of SWI/SNF complex-deficient sinonasal carcinomas in a Southeast Asian cohort.

IF 2.3 3区医学 Q1 OTORHINOLARYNGOLOGY Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2024-07-05 DOI:10.1002/hed.27864

Xinni Xu, Bingcheng Wu, Kwok Seng Loh, Wei Sian Lim, Charmaine Si Min Tan, Terese Huiying Low, Yew Kwang Ong, Jeng Swan Tan, Donovan Kum Chuen Eu

{"title":"Outcomes of SWI/SNF complex-deficient sinonasal carcinomas in a Southeast Asian cohort.","authors":"Xinni Xu, Bingcheng Wu, Kwok Seng Loh, Wei Sian Lim, Charmaine Si Min Tan, Terese Huiying Low, Yew Kwang Ong, Jeng Swan Tan, Donovan Kum Chuen Eu","doi":"10.1002/hed.27864","DOIUrl":null,"url":null,"abstract":"Background: SWI/SNF complex-deficient sinonasal carcinomas are rare, genetically distinct, and aggressive entities.Methods: SMARCB1 and SMARCA4 immunohistochemistry was retrospectively performed on a cohort of undifferentiated, poorly differentiated, and poorly defined sinonasal carcinomas. Survival outcomes were compared between SMARCB1/SMARCA4 (SWI/SNF complex)-deficient and -retained groups.Results: Eight SWI/SNF complex-deficient (six SMARCB1-deficient, two SMARCA4-deficient) cases were identified among 47 patients over 12 years. Triple-modality treatment was more frequently utilized in SWI/SNF complex-deficient carcinomas than in SWI/SNF complex-retained carcinomas (71.4% vs. 11.8%, p = 0.001). After a median follow-up of 21.3 (IQR 9.9-56.0) months, SWI/SNF complex-deficient sinonasal carcinomas showed comparable recurrence rates (57.1% vs. 52.9%, p = 0.839), time-to-recurrence (7.3 [IQR 6.6-8.3] vs. 9.1 [IQR 3.9-17.4] months, p = 0.531), and overall survival (17.7 [IQR 11.8-67.0] vs. 21.6 [IQR 8.9-56.0] months, p = 0.835) compared to SWI/SNF complex-retained sinonasal carcinomas.Conclusion: Triple-modality treatment may improve survival in SWI/SNF complex-deficient sinonasal carcinomas.","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.27864","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: SWI/SNF complex-deficient sinonasal carcinomas are rare, genetically distinct, and aggressive entities.

Methods: SMARCB1 and SMARCA4 immunohistochemistry was retrospectively performed on a cohort of undifferentiated, poorly differentiated, and poorly defined sinonasal carcinomas. Survival outcomes were compared between SMARCB1/SMARCA4 (SWI/SNF complex)-deficient and -retained groups.

Results: Eight SWI/SNF complex-deficient (six SMARCB1-deficient, two SMARCA4-deficient) cases were identified among 47 patients over 12 years. Triple-modality treatment was more frequently utilized in SWI/SNF complex-deficient carcinomas than in SWI/SNF complex-retained carcinomas (71.4% vs. 11.8%, p = 0.001). After a median follow-up of 21.3 (IQR 9.9-56.0) months, SWI/SNF complex-deficient sinonasal carcinomas showed comparable recurrence rates (57.1% vs. 52.9%, p = 0.839), time-to-recurrence (7.3 [IQR 6.6-8.3] vs. 9.1 [IQR 3.9-17.4] months, p = 0.531), and overall survival (17.7 [IQR 11.8-67.0] vs. 21.6 [IQR 8.9-56.0] months, p = 0.835) compared to SWI/SNF complex-retained sinonasal carcinomas.

Conclusion: Triple-modality treatment may improve survival in SWI/SNF complex-deficient sinonasal carcinomas.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

东南亚队列中SWI/SNF复合体缺陷鼻窦癌的预后。

背景：SWI/SNF 复合物缺陷型鼻窦癌是一种罕见的、基因独特的侵袭性肿瘤：SWI/SNF复合体缺陷型鼻窦癌是一种罕见的、遗传学上独特的侵袭性实体：方法：对一组未分化、分化差和定义不清的鼻窦癌回顾性地进行了SMARCB1和SMARCA4免疫组化。比较了SMARCB1/SMARCA4（SWI/SNF复合体）缺失组和保留组的生存结果：在47名患者中发现了8例SWI/SNF复合体缺失病例（6例SMARCB1缺失，2例SMARCA4缺失），病程超过12年。与SWI/SNF复合体保留型癌相比，SWI/SNF复合体缺陷型癌更常采用三重模式治疗（71.4%对11.8%，P = 0.001）。中位随访 21.3（IQR 9.9-56.0）个月后，SWI/SNF 复合物缺陷型鼻窦癌的复发率（57.1% vs. 52.9%，p = 0.839）、复发时间（7.3 [IQR 6.6-8.3]个月 vs. 9.1 [IQR 3.9-17.4] 个月，p = 0.531），以及总生存期（17.7 [IQR 11.8-67.0] 个月 vs. 21.6 [IQR 8.9-56.0] 个月，p = 0.835）：结论：三联疗法可提高SWI/SNF复合体缺失型鼻窦癌患者的生存率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.